Leadership shift at Harrow (NASDAQ: HROW) subsidiary ImprimisRx

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Harrow, Inc. reported a leadership change at its wholly owned subsidiary ImprimisRx, LLC. On October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx and certain affiliated entities, effective that date. He has moved into a non-officer leadership role at Harrow and will no longer be involved in ImprimisRx’s operations. The company did not enter into any new compensatory arrangements with him in connection with this transition.

Harrow also issued a press release on October 6, 2025, announcing these leadership changes at ImprimisRx, which is furnished as an exhibit and incorporated by reference.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

10/06/2025 - 07:23 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2025

HARROW, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35814

45-0567010

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1A Burton Hills Blvd., Suite 200
Nashville, Tennessee		37215
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (615) 733-4730

	Not Applicable
	(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name on exchange on which registered
Common Stock, $0.001 par value per share	HROW	The Nasdaq Stock Market LLC
8.625% Senior Notes due 2026	HROWL	The Nasdaq Stock Market LLC
11.875% Senior Notes due 2027	HROWM	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company ☐

If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx, LLC and certain affiliated entities, each of which is a wholly owned subsidiary of Harrow, Inc. (the “Company”), effective that date. Mr. Saharek has transitioned to a non-officer leadership role at the Company and will no longer be involved in the operations of ImprimisRx. No new compensatory arrangements were entered into with Mr. Saharek in connection with this transition.

Item 7.01 Regulation FD Disclosure.

On October 6, 2025, the Company issued a press release announcing leadership changes at ImprimisRx. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d)		Exhibits

99.1		Press Release, dated October 6, 2025 (furnished herewith)

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HARROW, INC.

Dated: October 6, 2025	By:	/s/ Andrew R. Boll
		Andrew R. Boll
		President and Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did Harrow (HROW) disclose at ImprimisRx?

Harrow disclosed that on October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx, LLC and certain affiliated entities.

What is John Saharek’s new role at Harrow (HROW)?

John Saharek has transitioned to a non-officer leadership role at Harrow, Inc. and will no longer be involved in the operations of ImprimisRx.

Did Harrow (HROW) change John Saharek’s compensation as part of this transition?

No new compensatory arrangements were entered into with John Saharek in connection with his transition from President and CEO of ImprimisRx.

Which Harrow subsidiary is affected by the leadership change?

The leadership change affects ImprimisRx, LLC and certain affiliated entities, each of which is a wholly owned subsidiary of Harrow, Inc.

Did Harrow (HROW) issue a press release about the ImprimisRx leadership changes?

Yes. Harrow issued a press release on October 6, 2025, announcing leadership changes at ImprimisRx. The press release is furnished as Exhibit 99.1 and incorporated by reference.

Are the ImprimisRx leadership changes considered filed or furnished information?

The information provided under the leadership changes press release in Item 7.01, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.